Bliss GVS Pharma Ltd - 506197 - Intimation Of Recommendations By The Committee Of Independent Directors ('IDC') Pursuant To Regulation 26(7) Of The SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
Bliss GVS Pharma's Independent Directors Committee (IDC) has recommended public shareholders consider the open offer by Anupam Rasayan India Limited for acquiring up to 26% of the company's shares. The offer price is Rs. 299 per share, which is lower than the current market price of Rs. 482.50.
Jul 22 2026 19:09:34
Bliss GVS Pharma Ltd - 506197 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Clarus Capital I and its Persons Acting in Concert (PACs) acquired 1,84,652 shares of Bliss GVS Pharma through open market transactions. This acquisition increased their aggregate shareholding to 5.13%, crossing the regulatory 5% disclosure threshold.
Jul 22 2026 17:13:18
Bliss GVS Pharma Ltd - 506197 - Letter Of Offer Dated July 18, 2026 Received From SBI Capital Markets Limited
Bliss GVS Pharma received an open offer from Anupam Rasayan India for acquiring a 26% stake at ₹299 per share. This mandatory offer will result in a change of control.
Jul 21 2026 19:50:16
Bliss GVS Pharma Ltd - 506197 - Addendum To Public Announcement And Detailed Public Statement
Bliss GVS Pharma informed about an addendum to the public announcement for its open offer. Mates Visa Consultancy Private Limited has been added as a Person Acting in Concert with the acquirer, Anupam Rasayan India Limited, for the acquisition of 26.00% of Bliss GVS Pharma's equity shares.
Jul 19 2026 19:09:16
Bliss GVS Pharma Ltd - 506197 - Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, July 03, 2026
Bliss GVS Pharma appointed Mr. Rahul Adakmol as the new Chief Executive Officer, effective July 15, 2026. This follows Mr. Narsimha Shibroor Kamath stepping down from the CEO role but continuing as the Managing Director, ensuring a smooth leadership transition.
Jul 03 2026 18:50:30
Read More